Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Smoldering Multiple Myeloma × IPH-2101 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Smoldering Multiple Myeloma 1 Multiple Myeloma 1

Interventions

Dexamethasone 9 Lenalidomide 8 carfilzomib 4 Calcium Dobesilate 4 daratumumab 3 elotuzumab 2 Denosumab 2 selinexor 1 pomalidomide 1 piperine 1 ixazomib 1 isatuximab 1 ibrutinib 1 iberdomide 1 fludarabine phosphate 1 fludarabine 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 auricularum 1 Simvastatin 1 Nivolumab 1 Metformin 1 Melphalan 1 Leflunomide 1 IPH-2101 1 Gene Expression Profiling 1 Fatty Acids, Omega-3 1 Cyclophosphamide 1 Curcumin 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01222286 2014-05-09

KIRMONO

Innate Pharma

Phase 2 Completed

30 enrolled 10 charts

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡